Dr. James E. Loveless, MD

Dr. Loveless practices at St. Luke's Boise Medical Center in Boise, Idaho, part of St. Luke's Health System.

Dr. Loveless' NPI, 1396851341, was assigned on August 22, 2006. Dr. Loveless graduated from Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University in 1986. Dr. Loveless holds Idaho license M-6288.

Dr. Loveless' primary practice is St. Luke's Boise Medical Center, at 190 East Bannock Street, Boise, ID 83712 in Ada County. The practice phone is (208) 381-2222.

Dr. Loveless' primary practice is St. Luke's Boise Medical Center in Boise, Idaho, part of St. Luke's Health System. Dr. Loveless is also affiliated with Saint Alphonsus Regional Medical Center. The medical group on file is St. Luke's Health System. Dmand AI also links Dr. Loveless to 3 more hospitals and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Loveless practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Loveless' primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Loveless is licensed in Idaho.

CMS data shows 137 Medicare services from Dr. Loveless across 1 procedure code in 2024, all of them office visits, for 110 Medicare patients. Medicare paid $7,808 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 110 Medicare patients who saw Dr. Loveless in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have arthritis, and 65% have high blood pressure. Their average risk score is 1.38, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Loveless' median patient age at 68, with 72% women.

In 2024, Dr. Loveless wrote 1,336 Medicare Part D claims for 234 patients. 79% of them were for generic drugs. CMS names the drug for 1,184 of them, across 33 drugs with 11 or more claims each, at $1,020,301 in total drug cost. In 2023, CMS named 1,205 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Loveless for performance year 2024, reported as part of a group. Dr. Loveless accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Loveless as offering telehealth.

Dmand AI links 2 papers to Dr. Loveless, published from 2012 to 2021. Dr. Loveless' most frequent co-authors are Rachel Pam Baden, MD, Stanley Bruce Cohen, MD and Emma R. Kaplan-Lewis, MD.

Dmand AI links Dr. Loveless to 5 clinical trials. Conditions studied include Arthritis, Rheumatoid, Axial Spondyloarthritis and Rheumatic Diseases. Eli Lilly and Company sponsors the most, 4. Open Payments lists research payments to Dr. Loveless that name 2 trials.

CMS Open Payments shows 224 general payments to Dr. Loveless from 17 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Genentech, Inc. paid the most, $32,134. It also lists 3 research payments totaling $1,386 from 2021 to 2024, naming 2 clinical trials.

Dr. Loveless graduated from Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University in 1986.